Full Press Release Details
Apollomics Inc. Announces $2.0 Million Bridge Financing
FOSTER CITY, Calif., April 1, 2026 (GLOBE NEWSWIRE) - Apollomics Inc. (Nasdaq: APLM) ("Apollomics" or the
"Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the "Note") with Mr. Hung-Wen (Howard) Chen, the Company's
Chairman and Chief Executive Officer, on March 30, 2026.
The $2.0 million in proceeds from the Note are intended to provide the
Company with necessary working capital to support clinical development programs and general corporate operations.
unsecured obligation of the Company and carries a 0% interest rate. Under the terms of the agreement, the principal amount will automatically convert into equity securities of the Company upon the closing of a subsequent equity financing with
aggregate gross proceeds of at least $10.0 million. The conversion price will be calculated at a 20% discount to the lowest per-share price issued to investors in such financing.
The terms of the related-party transaction were reviewed and approved by the Company's independent Audit Committee and the Board of
Directors, with Mr. Chen abstaining from the vote. The transaction followed a comprehensive evaluation of the Company's financing alternatives and a benchmarking analysis against current market terms for similar bridge financing
transactions in the biotechnology sector.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to
be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in
a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including
Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present
or historical fact included in this press release, regarding Apollomics' strategy, prospects, plans, objectives, including with respect to the anticipated use of proceeds from the Note, the potential conversion
of the Note into equity securities, and the Company's future financing plans, are forward-looking statements. When used in this press release, the words "could,"
"should," "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "seek," "project," the negative of such terms
and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available
information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control
of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government
regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party
intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to
protect Apollomics' intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory
environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024 (filed with the SEC on April 3, 2025) under the heading
"Risk Factors" and the other documents filed, or to be filed, by Apollomics with the SEC. These SEC filings are available publicly on the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date made by
Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, except to the extent required by applicable law.
Peter Lin, Chief Financial Officer